Publication:
Profiling the immune landscape in mucinous ovarian carcinoma.

dc.contributor.authorMeagher, Nicola S
dc.contributor.authorHamilton, Phineas
dc.contributor.authorMilne, Katy
dc.contributor.authorThornton, Shelby
dc.contributor.authorHarris, Bronwyn
dc.contributor.authorWeir, Ashley
dc.contributor.authorAlsop, Jennifer
dc.contributor.authorBisinoto, Christiani
dc.contributor.authorBrenton, James D
dc.contributor.authorBrooks-Wilson, Angela
dc.contributor.authorChiu, Derek S
dc.contributor.authorCushing-Haugen, Kara L
dc.contributor.authorFereday, Sian
dc.contributor.authorGarsed, Dale W
dc.contributor.authorGayther, Simon A
dc.contributor.authorGentry-Maharaj, Aleksandra
dc.contributor.authorGilks, Blake
dc.contributor.authorJimenez-Linan, Mercedes
dc.contributor.authorKennedy, Catherine J
dc.contributor.authorLe, Nhu D
dc.contributor.authorPiskorz, Anna M
dc.contributor.authorRiggan, Marjorie J
dc.contributor.authorShah, Mitul
dc.contributor.authorSingh, Naveena
dc.contributor.authorTalhouk, Aline
dc.contributor.authorWidschwendter, Martin
dc.contributor.authorBowtell, David D L
dc.contributor.authorCandido Dos Reis, Francisco J
dc.contributor.authorCook, Linda S
dc.contributor.authorFortner, Renée T
dc.contributor.authorGarcía, María J
dc.contributor.authorHarris, Holly R
dc.contributor.authorHuntsman, David G
dc.contributor.authorKarnezis, Anthony N
dc.contributor.authorKöbel, Martin
dc.contributor.authorMenon, Usha
dc.contributor.authorPharoah, Paul D P
dc.contributor.authorDoherty, Jennifer A
dc.contributor.authorAnglesio, Michael S
dc.contributor.authorPike, Malcolm C
dc.contributor.authorPearce, Celeste Leigh
dc.contributor.authorFriedlander, Michael L
dc.contributor.authorDeFazio, Anna
dc.contributor.authorNelson, Brad H
dc.contributor.authorRamus, Susan J
dc.contributor.funderUK Research & Innovation (UKRI)
dc.contributor.funderMedical Research Council UK (MRC)
dc.date.accessioned2025-03-20T06:28:53Z
dc.date.available2025-03-20T06:28:53Z
dc.date.issued2023-01
dc.descriptionFunding This work was supported by the U.S. Army Medical Research and Materiel Command through the Ovarian Cancer Research Program under Award No. W81XWH-16-2-0010. We are grateful for financial support for this study from UNSW Faculty of Medicine and Health. Funding for this study came from the accelerator grant of NSW Health PhD Scholarship Program awarded to Nicola S Meagher.
dc.description.abstractMucinous ovarian carcinoma (MOC) is a rare histotype of ovarian cancer, with low response rates to standard chemotherapy, and very poor survival for patients diagnosed at advanced stage. There is a limited understanding of the MOC immune landscape, and consequently whether immune checkpoint inhibitors could be considered for a subset of patients.
dc.description.abstractWe performed multicolor immunohistochemistry (IHC) and immunofluorescence (IF) on tissue microarrays in a cohort of 126 MOC patients. Cell densities were calculated in the epithelial and stromal components for tumor-associated macrophages (CD68+/PD-L1+, CD68+/PD-L1-), T cells (CD3+/CD8-, CD3+/CD8+), putative T-regulatory cells (Tregs, FOXP3+), B cells (CD20+/CD79A+), plasma cells (CD20-/CD79a+), and PD-L1+ and PD-1+ cells, and compared these values with clinical factors. Univariate and multivariable Cox Proportional Hazards assessed overall survival. Unsupervised k-means clustering identified patient subsets with common patterns of immune cell infiltration.
dc.description.abstractMean densities of PD1+ cells, PD-L1- macrophages, CD4+ and CD8+ T cells, and FOXP3+ Tregs were higher in the stroma compared to the epithelium. Tumors from advanced (Stage III/IV) MOC had greater epithelial infiltration of PD-L1- macrophages, and fewer PD-L1+ macrophages compared with Stage I/II cancers (p = 0.004 and p = 0.014 respectively). Patients with high epithelial density of FOXP3+ cells, CD8+/FOXP3+ cells, or PD-L1- macrophages, had poorer survival, and high epithelial CD79a + plasma cells conferred better survival, all upon univariate analysis only. Clustering showed that most MOC (86%) had an immune depleted (cold) phenotype, with only a small proportion (11/76,14%) considered immune inflamed (hot) based on T cell and PD-L1 infiltrates.
dc.description.abstractIn summary, MOCs are mostly immunogenically 'cold', suggesting they may have limited response to current immunotherapies.
dc.description.peerreviewed
dc.format.page23-31
dc.format.volume168
dc.identifier.citationGynecol Oncol . 2023 Jan:168:23-31.
dc.identifier.journalGynecol Oncol
dc.identifier.pubmedID36368129
dc.identifier.urihttps://hdl.handle.net/20.500.12105/26527
dc.language.isoeng
dc.publisherElevier
dc.relation.publisherversionhttp:// doi: 10.1016/j.ygyno.2022.10.022.
dc.repisalud.institucionCNIO
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Genética Humana
dc.rights.accessRightsopen access
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectImmune infiltrate
dc.subjectMucinous ovarian carcinoma
dc.subjectRare histotype
dc.titleProfiling the immune landscape in mucinous ovarian carcinoma.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Profilingtheimmunelandscape-2023.pdf
Size:
1.05 MB
Format:
Adobe Portable Document Format